Market Closed -
Xetra
16:40:25 29/04/2024 BST
|
After market
19:50:17
|
65.65
EUR
|
-3.24%
|
|
64.58
|
-1.64%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,021
|
3,072
|
1,139
|
451
|
1,278
|
2,555
|
-
|
-
|
Enterprise Value (EV)
1 |
3,791
|
2,299
|
470.7
|
-116.7
|
1,278
|
2,449
|
2,315
|
2,017
|
P/E ratio
|
-38.9
x
|
31.6
x
|
-2.17
x
|
-2.99
x
|
-6.15
x
|
-16
x
|
-32.9
x
|
521
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
56
x
|
9.37
x
|
6.34
x
|
1.62
x
|
5.36
x
|
10.2
x
|
7.86
x
|
6.09
x
|
EV / Revenue
|
52.8
x
|
7.02
x
|
2.62
x
|
-0.42
x
|
5.36
x
|
9.74
x
|
7.12
x
|
4.81
x
|
EV / EBITDA
|
-37.3
x
|
64.4
x
|
-1.76
x
|
0.56
x
|
-5.28
x
|
-14.5
x
|
-22.7
x
|
-60
x
|
EV / FCF
|
-45.5
x
|
74.6
x
|
-0.97
x
|
0.32
x
|
-4.32
x
|
-8.28
x
|
-8.96
x
|
-
|
FCF Yield
|
-2.2%
|
1.34%
|
-103%
|
316%
|
-23.2%
|
-12.1%
|
-11.2%
|
-
|
Price to Book
|
10.2
x
|
4.95
x
|
4.64
x
|
2.87
x
|
26.1
x
|
-11.4
x
|
12.9
x
|
3.62
x
|
Nbr of stocks (in thousands)
|
31,708
|
32,739
|
34,141
|
34,141
|
37,593
|
37,663
|
-
|
-
|
Reference price
2 |
126.8
|
93.82
|
33.35
|
13.21
|
34.00
|
67.85
|
67.85
|
67.85
|
Announcement Date
|
18/03/20
|
15/03/21
|
16/03/22
|
15/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
71.76
|
327.7
|
179.6
|
278.3
|
238.3
|
251.6
|
324.9
|
419.7
|
EBITDA
1 |
-101.7
|
35.69
|
-267.5
|
-210.2
|
-241.9
|
-169.5
|
-102.2
|
-33.61
|
EBIT
1 |
-107.9
|
27.36
|
-277.6
|
-220.7
|
-252.5
|
-180.2
|
-82.12
|
29.21
|
Operating Margin
|
-150.4%
|
8.35%
|
-154.57%
|
-79.32%
|
-105.96%
|
-71.63%
|
-25.27%
|
6.96%
|
Earnings before Tax (EBT)
1 |
-106.5
|
22.49
|
-591.1
|
-319.6
|
-190.9
|
-147.6
|
-88.01
|
17.45
|
Net income
1 |
-103
|
97.89
|
-514.5
|
-151.1
|
-189.7
|
-181.9
|
-114.8
|
-15.15
|
Net margin
|
-143.56%
|
29.87%
|
-286.47%
|
-54.29%
|
-79.61%
|
-72.29%
|
-35.33%
|
-3.61%
|
EPS
2 |
-3.260
|
2.970
|
-15.40
|
-4.420
|
-5.530
|
-4.230
|
-2.063
|
0.1302
|
Free Cash Flow
1 |
-83.24
|
30.81
|
-485.3
|
-368.6
|
-296.2
|
-295.8
|
-258.3
|
-
|
FCF margin
|
-116.01%
|
9.4%
|
-270.19%
|
-132.48%
|
-124.29%
|
-117.59%
|
-79.5%
|
-
|
FCF Conversion (EBITDA)
|
-
|
86.34%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
31.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/03/20
|
15/03/21
|
16/03/22
|
15/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
269.7
|
41.24
|
52.9
|
41.5
|
59.4
|
95.8
|
81.6
|
62.3
|
53.2
|
63.8
|
59
|
55.37
|
49.86
|
51.52
|
54.57
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-79.34
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
163.5
|
-82.36
|
-94.3
|
-68
|
-55.1
|
-29.3
|
-68.37
|
-69.5
|
-50.5
|
-51
|
-81.4
|
-35.36
|
-41
|
-39.7
|
-37.87
|
-
|
Operating Margin
|
60.63%
|
-199.68%
|
-178.26%
|
-163.86%
|
-92.76%
|
-30.58%
|
-83.79%
|
-111.56%
|
-94.92%
|
-79.94%
|
-137.97%
|
-63.87%
|
-82.22%
|
-77.06%
|
-69.4%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-113
|
-
|
-122.7
|
-
|
-123
|
-
|
-44.4
|
-74
|
-119.1
|
46.7
|
-36.53
|
-36.53
|
-46.53
|
-50.53
|
-
|
Net income
1 |
179.8
|
-112.8
|
-
|
-122.7
|
-235
|
-122.9
|
329.4
|
-44.4
|
-74
|
-119.6
|
48.3
|
-46.42
|
-49.08
|
-56.95
|
-61.18
|
-
|
Net margin
|
66.66%
|
-273.42%
|
-
|
-295.66%
|
-395.62%
|
-128.29%
|
403.74%
|
-71.27%
|
-139.1%
|
-187.46%
|
81.86%
|
-83.84%
|
-98.44%
|
-110.54%
|
-112.12%
|
-
|
EPS
2 |
5.540
|
-3.300
|
-11.16
|
-3.590
|
-6.880
|
-3.600
|
9.650
|
-1.300
|
-2.160
|
-3.500
|
1.220
|
-0.3053
|
-1.246
|
-1.055
|
-1.391
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/08/20
|
10/11/21
|
16/03/22
|
04/05/22
|
03/08/22
|
16/11/22
|
15/03/23
|
03/05/23
|
09/08/23
|
15/11/23
|
13/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
230
|
772
|
668
|
568
|
-
|
106
|
241
|
538
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-83.2
|
30.8
|
-485
|
-369
|
-296
|
-296
|
-258
|
-
|
ROE (net income / shareholders' equity)
|
-23.3%
|
19.3%
|
-65.5%
|
-75.1%
|
-184%
|
-
|
-453%
|
-
|
ROA (Net income/ Total Assets)
|
-19.9%
|
9.08%
|
-24.4%
|
-6.1%
|
-8.58%
|
-12.9%
|
-8.29%
|
-
|
Assets
1 |
517.6
|
1,078
|
2,108
|
2,477
|
2,211
|
1,406
|
1,384
|
-
|
Book Value Per Share
2 |
12.40
|
19.00
|
7.190
|
4.610
|
1.300
|
-5.980
|
5.270
|
18.80
|
Cash Flow per Share
|
-2.540
|
1.060
|
-14.40
|
-10.70
|
-
|
-
|
-
|
-
|
Capex
1 |
3.1
|
4.46
|
3.81
|
1.93
|
2.87
|
6.76
|
5.66
|
5.68
|
Capex / Sales
|
4.32%
|
1.36%
|
2.12%
|
0.69%
|
1.21%
|
2.69%
|
1.74%
|
1.35%
|
Announcement Date
|
18/03/20
|
15/03/21
|
16/03/22
|
15/03/23
|
13/03/24
|
-
|
-
|
-
|
Last Close Price
67.85
EUR Average target price
58.71
EUR Spread / Average Target -13.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +93.09% | 2.73B | | +2.34% | 42.75B | | +47.70% | 41.61B | | +11.92% | 41.34B | | -8.83% | 26.59B | | +6.63% | 25.49B | | -23.01% | 18.12B | | +30.18% | 12.24B | | -2.17% | 11.76B | | +9.14% | 11B |
Other Biotechnology & Medical Research
|